FDA sends signal with tough questions of Lilly at cancer drug meeting

Eli Lilly and China-based partner Innovent Biologics will likely need to run an international clinical trial of their lung cancer immunotherapy for the Food and Drug Administration to consider approving the drug in the U.S.